中国泰凌医药集团有限公司（01011）于2026年1月1日披露，截至2025年12月31日的股份变动月报表显示，公司本月股本维持稳定，未有新增发行或回购注销活动。
本期普通股法定/注册股本仍维持在62,592,500,000股，面值每股0.0000008美元，对应注册股本50,074美元；优先股法定/注册股本稳定在32,500,000股，面值每股0.0000008美元，对应注册股本26美元。上述普通股与优先股合计注册股本为50,100美元，较上月无变动。
已发行普通股本月底结存为674,246,015股，与上月底持平；当月无增发、购回及库藏股变动。公司亦未披露任何新的期权、权证或可换股票据事项。截至2025年12月31日，公司总股本保持不变。
公司于公告中确认，所有股份变动事项均遵照香港联交所《上市规则》及相关法律规定执行。公告由执行董事吴铁签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.